WO2008138968A4 - Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg - Google Patents
Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg Download PDFInfo
- Publication number
- WO2008138968A4 WO2008138968A4 PCT/EP2008/055971 EP2008055971W WO2008138968A4 WO 2008138968 A4 WO2008138968 A4 WO 2008138968A4 EP 2008055971 W EP2008055971 W EP 2008055971W WO 2008138968 A4 WO2008138968 A4 WO 2008138968A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- drug
- azabicyclo
- ylmethyl
- oct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a dosage form comprising 10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, or at least one pharmaceutically acceptable salt of same, characterized in that it provides in a suitable form for oral administration a daily dose of 1mg to 3 mg, and to the use of same to prepare a drug to prevent and/or treat allergic disorders, most notably allergic rhinitis.
Claims
AMENDED CLAIMS (received by the International Bureau on 15 May 2009)
1. A dosage form comprising a mixture of (R)- and (S) -enantioπiers of 10- [ 1-azabicyclo [2.2.2 ] oct-3- ylmethyl] -10#-phenothiazine containing between 95% and 100% by weight of the (S ) -enantiomer, preferably between 99% and 100% by weight of the (S) -enantiomer, or at least one pharmaceutically acceptable salt of same, characterized in that it provides in a suitable form for oral administration a daily dose of 1 mg to 3 mg.
2. The dosage form according to claim 1, characterized in that it provides in a suitable form for oral administration a daily dose of 1.5 mg to 2.5 mg .
3. The dosage form according to claim 1, characterized in that it is provided as a daily dosage unit comprising 1 mg to 3 mg of said mixture of enantiomers, or at least one pharmaceutically acceptable salt of same.
4. The dosage form according to claim 3, characterized in that said daily dosage unit comprises
1.5 mg to 2.5 mg of said mixture of enantiomers, or at least one pharmaceutically acceptable salt of same.
5. The dosage form according to any of the preceding claims, characterized in that it is provided in the form of a tablet, gelatin capsule, syrup, suspension or solution.
6. The dosage form according to any of the preceding claims, characterized in that said mixture of enantiomers of 10- [ 1-azabicyclo [2.2.2 ] oct-3-ylmethyl] - lOH-phenothiazine is essentially pure (S) -enantioraer .
7. Use of 10- [ (3S)-l-azabicyclo[2.2.2]oct-3- ylmethyl] -lOH-phenothiazine, or at least one pharmaceutically acceptable salt of same, to prepare a drug provided in a dosage form suitable for oral administration of a daily dose of 1 mg to 3 mg to prevent and/or treat allergic disorders.
8. Use according to claim 7, characterized in that said allergic disorders are allergic rhinitis.
9. Use according to claim 7, characterized in that said allergic disorders are allergic conjunctivitis.
10. Use according to any of claims 7 to 9, characterized in that said drug is provided in a dosage form suitable for oral administration of a daily dose of 1.5 mg to 2.5 mg.
11. Use according to any of claims 7 to 10, characterized in that said drug is provided as a daily dosage unit comprising 1 mg to 3 mg of 10- [ (3S)-I-
azabicyclo [2.2.2] oct-3-ylmethyl] -10H- phenothiazine, or at least one pharmaceutically acceptable salt of same.
12. Use according to claim 9, characterized in that said drug is provided as a daily dosage unit comprising 1.5 mg to 2.5 mg of 10- [ (3S)-I- azabicyclo [2.2.2] oct-3-ylmethyl] -lOH-phenothiazine, or at least one pharmaceutically acceptable salt of same.
13. Use according to any of claims 7 to 12, characterized in that said drug is to prevent and/or treat dermatological symptoms caused by a release of histamine or by an abnormally high level of IgE, such as chronic idiopathic urticaria.
14. Use according to any of claims 7 to 13, characterized in that said drug minimizes the appearance of adverse effects, such as sedative effects .
15. Use according to any of claims 7 to 14, characterized in that said drug is used in combination with another active ingredient selected among antihistamines, lipoxygenase inhibitors, anti- inflammatories, inhibitors of pro-inflammatory cytokine release, leukotriene receptor antagonists, or compounds that control the release of mediators from mast cells, such as leukotrienes, prostaglandins, thromboxane A2 or platelet-activating factor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0755075 | 2007-05-15 | ||
| FR0755075A FR2916142A1 (en) | 2007-05-15 | 2007-05-15 | PHARMACEUTICAL FORM COMPRISING (10 - [(3S) -1-AZABICYCLO [2.2.2] OCT-3-YLMETHYL] -10H-PHENOTHIAZINE PRESENTING IN AN APPROPRIATE FORM FOR ADMINISTRATION OF A DAILY DOSE UNDER BETWEEN 1 AND 3 MG |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2008138968A2 WO2008138968A2 (en) | 2008-11-20 |
| WO2008138968A3 WO2008138968A3 (en) | 2009-05-22 |
| WO2008138968A4 true WO2008138968A4 (en) | 2009-07-02 |
Family
ID=38752476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2008/055971 Ceased WO2008138968A2 (en) | 2007-05-15 | 2008-05-15 | Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR066587A1 (en) |
| FR (1) | FR2916142A1 (en) |
| TW (1) | TW200906417A (en) |
| WO (1) | WO2008138968A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019099995A1 (en) * | 2017-11-17 | 2019-05-23 | Neurana Pharmaceuticals, Inc. | Methods of administering tolperisone |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2522660A1 (en) * | 1982-03-05 | 1983-09-09 | Pharmuka Lab | MEQUITAZINE LEVOGYER ISOMER, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME |
| JPH07188040A (en) * | 1993-12-27 | 1995-07-25 | Taisho Pharmaceut Co Ltd | Composition for treating rhinitis |
| FR2772029B1 (en) * | 1997-12-08 | 2000-02-25 | Pf Medicament | PROCESS FOR THE PREPARATION OF MEQUITAZINE AND NOVEL SYNTHESIS INTERMEDIATE |
| JP2000191536A (en) * | 1998-10-20 | 2000-07-11 | Taisho Pharmaceut Co Ltd | Oral solid preparation containing mequitazine |
| WO2005037245A2 (en) * | 2003-10-21 | 2005-04-28 | Direct-Haler A/S | A multiple route medication for the treatment of rhinitis and asthma |
| JP2006096749A (en) * | 2004-08-31 | 2006-04-13 | Takeda Chem Ind Ltd | Medicine composition for common cold |
| FR2896690B1 (en) * | 2006-01-30 | 2008-05-02 | Pierre Fabre Medicament Sa | USE OF MEQUITAZINE ENANTIOMER (S) FOR THE PREPARATION OF A MEDICINAL PRODUCT WHILE LIMITING GENOMIC TOXICITY |
-
2007
- 2007-05-15 FR FR0755075A patent/FR2916142A1/en not_active Withdrawn
-
2008
- 2008-05-13 TW TW097117537A patent/TW200906417A/en unknown
- 2008-05-15 AR ARP080102067A patent/AR066587A1/en unknown
- 2008-05-15 WO PCT/EP2008/055971 patent/WO2008138968A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AR066587A1 (en) | 2009-09-02 |
| TW200906417A (en) | 2009-02-16 |
| WO2008138968A2 (en) | 2008-11-20 |
| WO2008138968A3 (en) | 2009-05-22 |
| FR2916142A1 (en) | 2008-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060199805A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders | |
| US20060258640A1 (en) | Use of Flibanserin in the treatment of chronic pain | |
| WO2000010551A3 (en) | Methods of using and compositions comprising dopamine reuptake inhibitors | |
| JP2011520981A5 (en) | ||
| CA2508611A1 (en) | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines | |
| SK105698A3 (en) | Method of treatment and pharmaceutical composion | |
| EP2520296A1 (en) | New association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing it. | |
| JP2021001221A (en) | Iloperidone metabolite for use in treatment of psychiatric disorders | |
| JP2018039810A5 (en) | ||
| US20050038018A1 (en) | Meloxicam compositions | |
| WO2008138968A4 (en) | Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg | |
| US5021448A (en) | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist | |
| US20220347151A1 (en) | Transdermal pharmaceutical formulations for the treatment of chronic pain | |
| FR2915098A1 (en) | USE OF 4-CYCLOPROPYLMETHOXY-N- (3,5-DICHLORO-1-OXYDO-PYRIDIN-4-YL) -5- (METHOXY) PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF TRAUMATISMS OF SPINAL CORD | |
| JP2008100924A (en) | Combined preparation of combination cold remedy | |
| WO2015157729A1 (en) | Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant | |
| CL2008003066A1 (en) | Compounds derived from 1- [3- (phenylamino) -5- (pyridin-4-yl) -1h-1,2,4-triazol-1-yl] -alkyl-2-ol; pharmaceutical composition; process for preparing said composition; and use for the treatment or prevention of a disease of the central nervous system. | |
| WO2008065144A3 (en) | Galenic formulations of organic compounds | |
| PL208258B1 (en) | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts | |
| CA2328074A1 (en) | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | |
| WO2013083887A1 (en) | Novel association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide and an nmda receptor antagonist and the pharmaceutical compositions which contain said association | |
| WO2024243488A3 (en) | Formulations containing tryptamine derivatives and uses thereof | |
| BRPI0908988A2 (en) | oral galenic formulation including ketorolac and B vitamins, in which vitamin B6 is in an outer layer separate from the rest of the active ingredients | |
| RU2010125711A (en) | MEKVITAZIN FOR TREATMENT OR PREVENTION OF PATHOLOGIES IN WHICH H4 HISTAMINE RECEPTORS ARE Involved | |
| FR2579893A1 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08750306 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08750306 Country of ref document: EP Kind code of ref document: A2 |